Search
Sitaxentan
go.drugbank.com/drugs/DB06268ApprovedWithdrawnSitaxentan was marketed under the trade name Thelin for the treatment of pulmonary arterial hypertension (PAH) by Encysive Pharmaceuticals until Pfizer purchased Encysive in February 2008.
Isoxicam
go.drugbank.com/drugs/DB08942ApprovedWithdrawnIsoxicam is a non-steroidal anti-inflammatory drug that is not marketed in the United States.
Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDSTaletrectinib
go.drugbank.com/drugs/DB18711ApprovedInvestigational[A274118] Taletrectinib was approved by the US FDA in June 2025 for use in patients with advanced ROS1-positive NSCLC.[L53308,L53523] … [L53308] Gene fusions involving _ROS1_, a proto-oncogene, have been identified as oncogenic drivers in 1-2% of patients with non-small cell lung cancer (NSCLC), in addition to other cancers at variable
Tovorafenib
go.drugbank.com/drugs/DB15266ApprovedInvestigational[A263597] It was granted accelerated approval by the FDA, making it the first FDA approval of a systemic therapy for the treatment of pediatric low-grade glioma, with BRAF rearrangements. … [A263602] Tovorafenib inhibits BRAF and blocks dysregulated signalling pathways related to cancer cell growth and survival.[L50587]
Synonyms: 4-Pyrimidinecarboxamide, 6-amino-5-chloro-N-[(1R)-1-[5-[[[5-chloro-4-(trifluoromethyl)-2-pyridinyl]amino]carbonyl]-2-thiazolyl]ethyl]-, 6-amino-5-chloro-N-[1R)-1-[5-[[[5-hloro-4-(trifluoromethyl)-2pyridinyl]amino]carbonyl]-2-thiazoyl]ethyl]-4-pyrimdinecarboxamideOxazepam
go.drugbank.com/drugs/DB00842Approvedas compared to other benzodiazepines, and is likely owing in part to oxazepam's relatively simple metabolism. … Oxazepam, like related 3-hydroxybenzodiazepine [lorazepam], is considered less susceptible to pharmacokinetic variability based on patient-specific factors (e.g. age, liver disease) - this feature is advantageous
Formebolone
go.drugbank.com/drugs/DB01569IllicitInvestigationalIt is on the list of substances prohibited by the Word Anti-Doping Agency, and is regularly screened for in athletes. … [A14416] It is also classified by the US Drug Enforcement Administration as Schedule III drug in the Controlled Substances Act.
Cyclophosphamide
go.drugbank.com/drugs/DB00531ApprovedInvestigationalPrecursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide.
Synonyms: N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxideLatanoprostene bunod
go.drugbank.com/drugs/DB11660ApprovedLatanoprostene bunod is the first prostaglandin analog with one of its metabolites being nitric oxide (NO). … The novelty of this agent subsequently lies in the proposed dual mechanism of action that stems from both its prostaglandin F2-alpha analog latanoprost acid metabolite and its ability to donate NO for
Udenafil
go.drugbank.com/drugs/DB06267ApprovedIt is not yet approved for use in the U.S., E.U., or Canada. … Udenafil is a new phosphodiesterase type 5 (PDE5) inhibitor used to treat erectile dysfunction (ED). It has been approved in South Korea and will be marketed under the brand name Zydena.
N-methylnicotinamide
go.drugbank.com/drugs/DB08840InvestigationalIt is a metabolite of niacinamide/nicotinamide and niacin/nicotinic acid (vitamin B3), and as such N-methylnicotinamide is used to diagnose niacin deficiency by measuring N-methylnicotinamide in the urine … N-methylnicotinamide is an experimental drug with no approved indication or marketed formulation.
Synonyms: N-Methyl nicotineamide, 3-(N-Methylcarbamoyl)pyridine